Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Caribou Biosciences, Inc.NASDAQ: CRBU
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $649K fell 44.3% year over year, behind the -28.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Depreciation & amortization amounted to 32.7% of revenue in FY2025, down 6.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -44.3% toward the trailing-twelve-month pace of -28.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.65M USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- +38.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.65M | -7.2% |
| FY2024 | 2024-12-31 | 3.93M | +11.4% |
| FY2023 | 2023-12-31 | 3.53M | -3.2% |
| FY2022 | 2022-12-31 | 3.64M | +270.0% |
| FY2021 | 2021-12-31 | 984K | — |
Depreciation & Amortization vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.6% is the 9th highest of 11, against a peer median of -7.2%.
- Depreciation & amortization amounts to 27.9% of revenue for CRBU, versus a peer median of 20.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.13M USD | -8.0% | -4.7% | — | |
| LTM Mar 2026 | $7.54M USD | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $7.3M USD | +0.4% | -3.6% | 362.3% | |
| LTM Mar 2026 | $4.93M USD | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $4.42M USD | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.13M USD | -28.6% | +0.0% | 27.9% | |
| FY2025 | €2.8M EUR | -46.2% | +47.6% | 62.4% | |
| LTM Mar 2026 | $2.79M USD | -10.3% | +0.1% | 9.9% | |
| LTM Mar 2026 | $1.67M USD | -6.4% | +8.9% | 10.0% | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
| LTM Mar 2026 | $42K USD | -31.1% | -31.1% | — | |
| Peer median (excluding CRBU) | — | -7.2% | +4.5% | 20.9% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.6M | 13.85M | 34.48M | 9.99M | 11.16M |
| Cost of Revenue | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Gross Profit | 8.61M | 10.21M | 30.95M | 6.07M | 7.51M |
| Gross Margin | 89.7% | 73.7% | 89.8% | 60.7% | 67.3% |
| Research & Development | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M |
| Selling, General & Admin | 23.34M | 38.02M | 38.46M | 46.46M | 37.91M |
| Operating Expenses | 75.59M | 116.61M | 147.01M | 172.68M | 143.71M |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| EBITDA | (65.61M) | (95.71M) | (98.35M) | (145.19M) | (145.03M) |
| EBITDA Margin | -683.6% | -691.0% | -285.3% | -1452.7% | -1299.7% |
| Operating Income | (66.98M) | (106.4M) | (116.06M) | (166.62M) | (136.19M) |
| Operating Margin | -697.8% | -768.2% | -336.6% | -1667.2% | -1220.5% |
| Interest Income | 148K | 4.6M | 10.7M | 0 | 8M |
| Interest Expense | 8K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 377K | 7.05M | 14.18M | 17.5M | (12.48M) |
| Income Before Tax | (66.6M) | (99.35M) | (101.88M) | (149.11M) | (148.68M) |
| Pre-Tax Margin | -693.9% | -717.3% | -295.5% | -1492.0% | -1332.3% |
| Income Tax Expense | 321K | 70K | 193K | (9K) | (550K) |
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Net Margin | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
| EPS (Basic) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| EPS (Diluted) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| Weighted Avg Shares | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
| Weighted Avg Shares (Diluted) | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.